UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system.
Cory R. Nicholas, PhD, Co‑founder and CEO of Neurona Therapeutics, and UCSF professor, said:
“We are thrilled that UCB, a global leader in epilepsy science, recognizes the promise of our platform and programs. Their deep expertise, global reach, and long‑standing commitment to the epilepsy community make them an ideal partner to accelerate the development of NRTX‑1001 for temporal lobe epilepsy. Additionally, the proposed acquisition highlights UCB’s commitment to scientific innovation, representing foundational synergy between the two organizations that will undoubtedly unlock the broad potential of Neurona Therapeutics' regenerative pipeline. We are grateful to UCB for their investment and support these past years, and we are delighted for the opportunity to work hand-in-hand with the broader UCB family to bring transformative cell therapies to patients around the world."